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to oxidized lipids are the mechanisms by which GPx4 inhibits atherogenesis. Unexpectedly,
heterozygous mutation to GPx4 did not increase atherosclerotic lesions and oxidized lipids in
ApoE-/- mice.
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Strong evidence supports a role for CD40L as marker and mediator of inflammatory diseases
such as atherosclerosis. Despite extensive characterization of CD40, the classical receptor for
CD40L, in immune defense, its role in inflammatory diseases remains uncertain. This study
aimed to characterize the contribution of CD40 signaling to atherogenesis. Surprisingly, mice
deficient in both CD40 and the low-density lipoprotein-receptor (LDLR) do not develop smaller
lesions in the aortic arch, root, and thoraco-abdominal aorta compared to LDLR single-deficient
mice that consumed an atherogenic diet for 8 and 16 weeks. Lesions in these two groups of
mice also had similar composition. Based on previous reports demonstrating functional binding
of GPIIbIIIa to CD40L in thrombosis, we investigated other integrins as potential alternative
receptors for CD40L. We demonstrated that CD40L interacts with the integrin Mac-1 on human
monocyte/macrophages (using flow cytometry, radioactive binding assays, and immunopre-
cipitation), resulting in Mac-1-dependent adhesion and migration of inflammatory cells as well
as myeloperoxidase release in vitro. Furthermore, mice deficient in CD40L show significantly
reduced thioglycolate-elicited accumulation of inflammatory cells in the peritoneal cavity
compared with mice deficient in CD40 and wild-type controls. Inhibition of Mac-1 in
LDLR-deficient mice attenuates lesion development and reduces lesional macrophage accu-
mulation. These observations identify the interaction of CD40L and Mac-1 as an alternative
pathway for CD40L-mediated inflammation. This novel mechanism expands understanding of
inflammatory signaling during atherogenesis and has implications regarding novel anti-
inflammatory therapies.
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Structure-Function of Apolipoprotein A-IMilano and Related Variants
Eric T Alexander, Michael C Phillips, Children’s Hosp of Philadelphia, Philadelphia, PA;
Daniel J Rader; Univ of Pennsylvania Med Cntr, Philadelphia, PA
Epidemiological studies have shown that plasma apolipoprotein A-I (apoA-I) and high density
lipoprotein (HDL) cholesterol levels have an inverse relationship with the risk of developing
atherosclerosis. The naturally occurring mutation R173C apoA-I, or apoA-IMilano, belies that
correlation in that individuals heterozygous for this mutation have reduced plasma levels of
apoA-I and HDL, but are not at a greater risk for cardiovascular disease. The hypothesis being
investigated here is that the altered cardioprotective ability of apoA-IMilano is specifically related
to the introduction of a cysteine residue into the apoA-I primary sequence at position 173 and
not the loss of the arginine residue. To address this question, we engineered two mutations of
apoA-I, R173K apoA-I and R173S apoA-I. R173K apoA-I is a conservative mutation that
maintains the positive charge at position 173 whereas R173S apoA-I closely mimics the
apoA-IMilano mutation in that the structure of serine is very similar to cysteine, except for the
presence of a hydroxyl group rather than a sulfhydryl group. The proteins have been physically
characterized. ApoA-IMilano is less stable than WT apoA-I and has less alpha-helical content.
R173S apoA-I resembles apoA-IMilano while R173K apoA-I is almost identical to WT apoA-I.
Adeno-associated viruses containing the mutant apoA-I genes were generated and used to
infect apoA-I -/- mice. The plasma lipoprotein profile of mice expressing R173K apoA-I was
indistinguishable from that of mice expressing WT apoA-I. However, mice expressing either
R173S apoA-I or apoA-IMilano had reduced apoA-I levels and HDL cholesterol levels compared
to WT apoA-I. Mice expressing WT apoA-I had plasma HDL cholesterol concentrations of 80 
13mg/dl while mice expressing apoA-IMilano had only 31  2mg/dl. Interestingly, mice
expressing R173S apoA-I displayed an intermediate phenotype with plasma HDL cholesterol
levels of 48  5mg/dl. In summary, the altered structure and function of apoA-IMilano is due both
to the loss of a positive charge at position 173 and to the introduction of the cysteine residue
which allows the formation of disulfide bonds.
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Human apolipoprotein A-V (apoA-V) is a potent modulator of plasma triacylglycerol (TG) levels.
To probe different regions of this 343 amino acid protein, 4 single Trp apoA-V variants were
prepared. The variant with a Trp at position 325, distal to the tetra-proline sequence at residues
293–296, displayed an 8 nm blue shift in wavelength of maximum fluorescence emission upon
lipid association. To evaluate the structural and functional role of this 51-residue C-terminal
segment, a truncated apoA-V, comprising amino acids 1–292, was generated. Far UV circular
dichroism spectra of full-length apoA-V and apoA-V(1–292) were similar with 50% alpha
helix content. In guanidine HCl denaturation experiments, both full-length and truncated apoA-V
yielded biphasic profiles consistent with the presence of two structural domains. The
denaturation profile of the lower stability component, but not the higher stability component,
was affected by the truncation. In fluorescent dye binding experiments, apoA-V(1–292)
contained fewer solvent exposed hydrophobic sites than full-length apoA-V. Truncated apoA-V
displayed an attenuated ability to solubilize DMPC phospholipid vesicles compared to full-length
apoA-V yet it bound to a triolein/water interface with faster kinetics. Taken together, the data
support the concept that the 51 amino acid segment C-terminal to the tetra-proline sequence,
is not required for apoA-V to adopt a folded protein structure yet functions to modulate apoA-V
lipid binding activity and thereby, may be relevant to the mechanism whereby it influences
plasma TG levels.
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Disruption of Glycosylation at Asparagine-116 of Endothelial Lipase
Enhances Activity and Lipoprotein Lipid Hydrolysis in Vitro and in Vivo
Robert J Brown, Gwen C Miller, Nathalie Griffon, Christopher J Long, Daniel J Rader; Univ
of Pennsylvania, Philadelphia, PA
We previously identified that four of five putative N-linked glycosylation sites of human
endothelial lipase (EL) are utilized, and showed that substitution of the carbohydrate-linked
Asn-116 with Ala (N116A) increased the hydrolytic activity of EL. We expanded this observation
by first assessing the catalytic activities of additional mutants of the Asn-Asn-Thr glycosylation
sequence: Asn-116 to Thr (N116T), Asn-117 to Ala (N117A), and Thr-118 to Ala (T118A). The
specific activities of N116T- and T118A-EL were significantly enhanced toward dipalmi-
toylphosphatidyl choline (250  30% and 372  33%, respectively, p0.001) versus both
wild-type (WT)- and N117A-EL (100  25% and 121  11%, respectively). The specific
activities of N116T- and T118A-EL toward triolein were also significantly greater (294  14%
and 269  6%, respectively, p0.001) versus both WT- and N117A-EL (100  20% and
100  26%, respectively). These data demonstrate that it is the loss of glycosylation at
Asn-116, and not a structural effect of specifically the N116A mutant, that results in enhanced
catalytic activity of EL. We next assessed the hydrolysis of native lipoprotein lipids by
N116A-EL. Compared to WT-EL, the N116A mutant exhibited a significant 5-fold increase in
low density lipoprotein (LDL) hydrolysis and a 1.8-fold increase in high density lipoprotein (HDL)
2 hydrolysis; HDL3 hydrolysis was unchanged. Consistent with these observations, adenoviral-
mediated expression of N116A-EL (3 x 1010 virus particles per mouse) in LDL-receptor-null
mice significantly reduced levels of both HDL cholesterol (8.3  1.9 mg/dl, p0.03) and
non-HDL cholesterol (37.8  9.7 mg/dl, p0.03) beyond the reductions observed by the
expression of WT-EL alone (30.8  9.7 and 81.8  13.8 mg/dl, respectively). Finally, we
introduced Asn-116 of EL into the analogous positions within lipoprotein lipase (LPL) and
hepatic lipase (HL), resulting in N-linked glycosylation at this site. Glycosylation at this site
significantly suppressed LPL hydrolysis of synthetic substrates, LDL, HDL2, and HDL3, but had
little effect on HL activity. Overall, these data show that N-linked glycosylation at Asn-116 of
EL, or the analogous site of LPL, reduces hydrolysis of lipids within synthetic and lipoprotein
substrates.
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Carriers of the apolipoprotein A-IMilano (apoA-IM) mutant show severe reductions in the
plasma concentration of antiatherogenic HDL but do not present with preclinical atherosclerosis
and premature CHD. Aim of the present study was to investigate endothelial function in A-IM
carriers, since low HDL-C levels have been associated with features of endothelial dysfunction.
Plasma concentrations of soluble cell adhesion molecules (sCAMs) and forearm arterial
compliance (FAC) during reactive hyperemia were evaluated in 21 A-IM carriers, 21 healthy
subjects with low HDL-C, and 42 controls. Low HDL-C subjects had significantly higher plasma
sCAM levels than controls (sVCAM-1: 656.349.3 vs 502.625.5 ng/ml; sICAM-1:
335.621.5 vs 267.08.9 ng/ml; sE-selectin: 62.94.1 vs 47.93.0 ng/ml); on the contrary,
no differences were detected between A-IM carriers (sVCAM-1: 550.632.1 ng/ml; sICAM-1:
309.826.9 ng/ml; sE-selectin: 52.34.3 ng/ml) and controls. Low HDL-C subjects had lower
FAC than controls, while no differences were detected between A-IM carriers and controls.
These results suggest that HDL from A-IM carriers may be more efficient than control HDL in
modulating endothelial function. To test this hypothesis, plasma HDL were isolated from 6 A-IM
carriers and 6 controls, and their ability to inhibit VCAM-1 expression and to induce eNOS was
tested in cultured endothelial cells. A-IM HDL were two times more effective than control HDL
in reducing TNFalpha-induced VCAM-1 expression; the inhibition occurred at a transcriptional
level, as demonstrated by RT-PCR. In addition, cells exposed to A-IM HDL showed higher
expression of eNOS than cells treated with control HDL. In conclusion, despite the very low
HDL-C levels, A-IM carriers do not display features of endothelial dysfunction, such as the
increase of circulating sCAM levels and the impairment of arterial compliance, probably
because of a superior ability of A-IM HDL to protect the endothelium.
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Humans exhibit a heterogeneous HDL profile (i.e. HDL2 and HDL3), in contrast to other species
(e.g. mouse) that display a monophasic profile. HDL2 is thought to be more atheroprotective
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